Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment

May 4, 2025 updated by: NG Chi Fai, Chinese University of Hong Kong

A Study to Evaluate Patient and Physician Benefit/ Risk Preferences for Treatment of Metastatic Prostate Cancer (mPC) in Hong Kong: a Discrete Choice Experiment

The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

306

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

300 consecutive patients with metastatic prostate cancer (150 mHSPC and 150 mCRPC) within 5 years will be recruited

Description

Inclusion Criteria:

  • aged 18 years or older,
  • diagnosis of metastatic prostate cancer within 5 years,
  • able to read and write,
  • accepting and signing the informed consent

Exclusion Criteria:

  • if patients are unable to complete the survey by themselves due to physical or psychological reasons,
  • deemed ineligible by treating physicians if patients are unable to complete the survey by themselves due to physical or psychological reasons,
  • deemed ineligible by treating physicians

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient preferences for treatment attributes in prostate cancer from different stages of disease
Time Frame: 15 minutes (Once through survey)
Derived from discrete choice experiment
15 minutes (Once through survey)
The Preference weighting from Physicians involved in the treatment of prostate cancer in term of risk/benefit attributes of treatment.
Time Frame: 15 minutes (Once through survey)
Derived from discrete choice experiment.
15 minutes (Once through survey)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To examine the effect of socio-economic status on preference weighing
Time Frame: 15 minutes (Once through survey)
Derived from discrete choice experiment
15 minutes (Once through survey)
To examine their willingness of trading off survival with improving QOL
Time Frame: 15 minutes (Once through survey
Derived from discrete choice experiment
15 minutes (Once through survey
To examine the status of comorbidities on preference weighing
Time Frame: 15 minutes (Once through survey)
Derived from discrete choice experiment
15 minutes (Once through survey)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese University of Hong Kong

Investigators

  • Principal Investigator: Chi Fai NG, MD, Chinese University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 7, 2022

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

March 31, 2026

Study Registration Dates

First Submitted

February 28, 2023

First Submitted That Met QC Criteria

February 28, 2023

First Posted (Actual)

March 9, 2023

Study Record Updates

Last Update Posted (Actual)

May 6, 2025

Last Update Submitted That Met QC Criteria

May 4, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CRE-2022.301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe